CTLA4 and non-small cell lung carcinoma: That was to say, compared to patients with low m6Ascores, NSCLC patients with high m6Ascores exhibited a better therapeutic benefit and clinical response to anti-PD1 or anti-CTLA4 immunotherapy (Figure 7B).